EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of Eptifibatide on coronary flow reserve following coronary stent implantation (An ESPRIT substudy)



Effect of Eptifibatide on coronary flow reserve following coronary stent implantation (An ESPRIT substudy)



American Journal of Cardiology 87(11): 1293-1295



Eptifibatide administration was associated with improved CFR after stent placement and a greater rate of increase in the brightness of myocardial blush after adenosine administration using digital subtraction angiography. These findings suggest eptifibatide therapy is associated with improved microvascular perfusion after coronary stent implantation, although these findings require further prospective validation.

(PDF emailed within 0-6 h: $19.90)

Accession: 010513742

Download citation: RISBibTeXText

DOI: 10.1016/s0002-9149(01)01524-7



Related references

Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. American Journal of Cardiology 87(11): 1293-1295, 2001

Eptifibatide improves coronary flow reserve following stent placement An esprit substudy. Circulation 102(18 Supplement): II 366, October 31, 2000

Eptifibatide in coronary stent implantation Long-term results of the ESPRIT trial. Circulation 104(17 Supplement): II 94, October 23, 2001

High-dose eptifibatide in coronary stent implantation 6 Month results of the ESPRIT trial. Circulation 102(18 Supplement): II 663, October 31, 2000

High-dose eptifibatide in coronary stent implantation 1 Year results of the ESPRIT trial. Journal of the American College of Cardiology 37(2 Supplement A): 76A, February, 2001

High-dose eptifibatide in elective coronary stent implantation Results of the ESPRIT trial. European Heart Journal 21(Abstract Supplement): 146, August-September, 2000

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 356(9247): 2037-2044, 2001

Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo-controlled study. Indian Heart Journal 53(3): 376-376, 2001

Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT trial). American Journal of Cardiology 91(1): 17-21, 2003

Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). American Journal of Cardiology 91(1): 17-21, 2002

In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. American Journal of Cardiology 89(1): 61-64, 2002

Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy). American Journal of Cardiology 94(7): 926-929, 2004

Relative but not absolute postinterventional coronary flow velocity reserve predicts release of ischemia markers after uncomplicated coronary stent implantation. Circulation 104(17 Supplement): II 457, October 23, 2001

Differences of regional coronary flow reserve assessed by adenosine thallium-201 scintigraphy early and six months after successful percutaneous transluminal coronary angioplasty or stent implantation. American Journal of Cardiology 78(10): 1097-1102, 1996

Treatment effect at different levels of creatinine clearance following eptifibatide in planned coronary stent implantation. Journal of the American College of Cardiology 37(2 Supplement A): 11A, February, 2001